Atrium acquires Douglas Laboratories Canada

Quebec City, QC – Atrium Biotechnologies says it has acquired the assets of London, ON-based Douglas Laboratories. The latter has been marketing its products in Canada since 2000 and has current annual revenues of approximately $5 million.

“This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada, says Richard Bordeleau, president of Atrium’s health & nutrition division.

In addition, Atrium says it will be able to benefit from the expertise and support of Douglas current management and staff who are staying on to ensure the successful integration and to sustain its growth.